Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 27 June 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Response to therapy among patients with acute exacerbation of chronic Hep C

The latest issue of Clinical Gastroenterology & Hepatology investigates clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic Hepatitis C.

News image

The slow asymptomatic progression of chronic hepatitis C can be interrupted by an acute exacerbation, characterized by increased serum levels of alanine aminotransferase and bilirubin and other symptoms of acute hepatitis.

Dr Evangelista Sagnelli and colleagues provided more information about the clinical presentation of acute exacerbation of chronic hepatitis C.

The research team identified 82 consecutive patients, from 2 locations in Italy, who had an acute exacerbation of chronic hepatitis C from 2005 through 2010.

The team followed them up for a median period of 36 months.

Hepatitis C virus genotype 2 was detected in 46% of cases
Clinical Gastroenterology and Hepatology

These cases were hepatitis C virus RNA positive, hepatitis B surface antigen-negative, and had not received anti-hepatitis C virus therapy.

The cases were matched with 82 subjects with hepatitis C without reactivation for age, sex, and hepatitis C virus genotype.

The researchers followed 69 cases, and 73 controls were followed up for at least 2 years.

Liver biopsy specimens had been taken from 23 cases and 31 controls—once before enrollment in the study and once during the follow-up period.

The research team detected hepatitis C virus genotype 2 in 46% of cases, and hepatitis C virus genotype 1 was detected in 44%.

Among cases, the mean alanine aminotransferase level was 1063 IU/dL, and the mean total bilirubin level was 16 mg/dL.

The doctors analyzed a higher percentage of cases carried the interleukin-28B CC genotype than controls.

Among cases, 44% had a steady increase in alanine aminotransferase level for 56% of these patients, alanine aminotransferase levels returned to baseline values before the acute exacerbation of chronic hepatitis.

Based on comparisons of biopsy specimens, 18 cases and 11 controls had increasing fibrosis, with Ishak scores increasing by more than 2.

The team found that 14 cases and 3 controls had increases in necroinflammation of more than 2 points.

The researchers observed that 32 cases and 38 controls received treatment with pegylated interferon and ribavirin.

A sustained virologic response was achieved in 26 cases and 23 controls.

Dr Sagnelli's team commented, "Although an acute exacerbation of chronic hepatitis is a serious medical condition, most patients achieve a sustained virologic response after treatment with pegylated interferon and ribavirin."

Clin Gastroenterol and Hepatol 2013: 11(9): 1174-1180
19 September 2013

Go to top of page Email this page Email this page to a colleague

 27 June 2016 
The Toronto Consensus for H. pylori treatment
 27 June 2016 
Epidemiology of NAFLD
 27 June 2016 
Tobacco smoking and ulcerative colitis
 24 June 2016 
Dietary trends in the USA
 24 June 2016 
Statins and colorectal cancer in IBD
 24 June 2016 
Fibre for chronic idiopathic constipation
 23 June 2016 
Biomarker for eosinophilic esophagitis diagnosis
 23 June 2016 
Adverse events after colonoscopy bowel preparations
 23 June 2016 
Touch screens in the IBD outpatient clinic
 22 June 2016 
Benefits and harms of colorectal cancer screening
 22 June 2016 
IBS symptoms in IBD
 22 June 2016 
Outcomes among US veterans with Hep B
 21 June 2016 
Screening for colorectal cancer
 21 June 2016 
Tenofovir and Hep B transmission in mothers
 21 June 2016 
Access to liver subspecialty care and survival
 20 June 2016 
Genes for colorectal cancer risk
 20 June 2016 
Patients and gastroenterologists’ perceptions on IBD
 20 June 2016 
Hep C treatment in people who inject drugs
 17 June 2016 
Noninvasive markers of liver fibrosis
 17 June 2016 
Predictors of starting with long-term PPIs
 17 June 2016 
Extrahepatic manifestations of Hep C
 16 June 2016 
Assessing progression of NAFLD
 16 June 2016 
Endotracheal intubation and endoscopy unit efficiency metrics
 16 June 2016 
Bile acid diarrhea
 15 June 2016 
Consensus for acute severe ulcerative colitis
 15 June 2016 
Dental erosions in GERD
 15 June 2016 
Pharmacological treatments for obesity with weight loss
 14 June 2016 
Antibiotics and gut inflammation
 14 June 2016 
Liver-related mortality in the developed world
 14 June 2016 
Hep C patient outcomes treated with different anti-viral regimens
 13 June 2016 
Obesity in the USA
 13 June 2016 
Celiac disease drug development
 13 June 2016 
Pneumonia risk in celiac disease
 10 June 2016 

Celiac disease drug development

 10 June 2016 
Rectal cancer surgery checklist
 10 June 2016 
Breath as a marker for IBS
 09 June 2016 
Psychological morbidity in young people with IBD
 09 June 2016 
Predicting hepatic encephalopathy in cirrhosis
 09 June 2016 
Evaluation of endoscopic findings from patients with Crohn's
 08 June 2016 
Adult obesity trends in the USA
 08 June 2016 
Pediatric IBD unclassified vs other IBD
 08 June 2016 
Dark chocolate and NASH oxidation
 07 June 2016 
Flexible endoscopy for Zenker's diverticulum
 07 June 2016 
Predicting risk of hepatic encephalopathy in cirrhosis
 07 June 2016 
Electronic learning system for colon capsule endoscopy
 06 June 2016 
Disturbed sleep and symptoms in IBS
 06 June 2016 
Oral contraceptives and Crohn’s complications
 06 June 2016 
Eosinophilic esophagitis
 03 June 2016 
Antibiotic prophylaxis in cirrhosis
 03 June 2016 
Mortality in hospitalized peptic ulcer patients
 03 June 2016 
Decision aid for surgical patients with ulcerative colitis
 02 June 2016 
Allergy tests for eosinophilic esophagitis
 02 June 2016 
Fatty liver disease and mortality
 02 June 2016 
Ethnic inequalities in rectal cancer care
 01 June 2016 
Predicting NASH resolution
 01 June 2016 
Predicting relapse in IBD
 01 June 2016 
Treatment of Hep C/HIV after liver transplant
 31 May 2016 
Markers as a reflection of inflammatory burden in ulcerative colitis
 31 May 2016 
Predicting Crohn's diseases before diagnosis
 31 May 2016 
Biomarker predicts post ERCP pancreatitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us